Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
53 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND bendamustine [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Condition: Marginal Zone B-cell Lymphoma
Intervention: Drug: bendamustine plus rituximab
2 Recruiting Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Rituximab, bendamustine
3 Recruiting A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Condition: Lymphoma, Mantle Cell
Interventions: Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
4 Recruiting Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Non-Hodgkin's Lymphoma
Interventions: Drug: Ublituximab + TGR-1202;   Drug: Ublituximab + TGR-1202 + ibrutinib;   Drug: Ublituximab + TGR-1202 + bendamustine
5 Recruiting A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)
6 Recruiting Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Lymphoid Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Rituximab;   Drug: Lenalidomid
7 Recruiting Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Cytarabine;   Drug: Pegfilgrastim;   Procedure: Leukapheresis;   Drug: Filgrastim;   Procedure: Autologous stem cell transplant
8 Recruiting Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Condition: Relapsed or Refractory Follicular Lymphoma
Interventions: Drug: INCB050465;   Drug: Hexal;   Drug: Gazyvaro
9 Recruiting Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Carboplatin;   Drug: Etoposide;   Procedure: CT Scan;   Procedure: PET Scan;   Genetic: Stem Cell Transplant (STC)
10 Recruiting BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)
Condition: Follicular Lymphoma
Intervention: Drug: BeEAM
11 Recruiting Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
Condition: Aggressive Lymphoma
Intervention: Drug: Bendamustine and subcutaneous rituximab
12 Recruiting Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: bendamustine, rituximab
13 Recruiting Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Rituximab
14 Recruiting BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Bendamustine
15 Recruiting Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Conditions: Diffuse Large B-cell Lymphoma Refractory;   Follicular B-cell Non-Hodgkin's Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Rituximab;   Drug: Bendamustine
16 Recruiting Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
Condition: Classical Hodgkin Lymphoma
Interventions: Drug: Bendamustine;   Drug: Prednisone;   Drug: Vinblastine;   Drug: Doxorubicin
17 Recruiting A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: TAK-659;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Lenalidomide;   Drug: Ibrutinib
18 Recruiting Observational Study in CLL Patients Receiving BR
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Bendamustine and Rituximab
19 Not yet recruiting Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Conditions: Follicular Lymphoma;   Non-Hodgkin's Lymphoma Follicular;   Non-Hodgkin's Lymphoma, Adult High Grade
Interventions: Drug: Induction Venetoclax;   Drug: Maintenance Venetoclax
20 Not yet recruiting CyBeR Association in Relapsed/Refractory DLBCL
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Cytarabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.